がん化学療法レジメン一覧【消化器内科】
食道がん
- DTX
- FOLFOX
- Nivolumab
- Pembrolizumab(ESCC, CPS≧10)(Q3W)
- Pembrolizumab(ESCC, CPS≧10)(Q6W)
- (持続注入)5-FU+Nivo(q2w)
- (持続注入)5-FU+Nivo(q4w)
- (持続注入)5-FU+Pembrolizumab
胃がん
- CapeOX
- CapeOX-T
- IRI
- IRI-T
- nabPTX (triweekly)
- nabPTX (weekly)
- wPTX＋Ram
- mFOLFOX6
- Nivolumab
- Ram
- SOX＋T
- T-DXd
- wPTX
- CapeOX+Nivolumab
- mFOLFOX6+Nivolumab
- SOX+Nivolumab
- 5-FU/LV(胃がん)
- Ram＋IRI
- FLOT(周術期)
- Nivolumab(q4w)
- FTD/TPI＋RAM
- CapeOX(周術期)
- SOX(周術期)
- DS(周術期)
- nabPTX＋RAM
- SOX＋Pembrolizumab
- SP＋Pembrolizumab
- S-1＋Pembrolizumab
- CapeOX+Pembrolizumab
- Cape+Pembrolizumab
- FP+Pembrolizumab
- 【持続注入】5-FU+Pembrolizumab
- mFOLFOX6+Zolbetuximab
- CapeOX＋Zolbetuximab
大腸がん
- CapeOX
- CapeOX+Bev
- FOLFIRI+Pmab
- IRI+Pmab
- IRIS+Pmab
- mFOLFOX6+Pmab
- Pmab
- FOLFIRI+Ram
- Cape＋Bev
- FOLFIRI+AFL
- FTD/TPI＋Bev
- Nivo+Ipi（MSI-H大腸がん）
- Pembrolizumab（MSI-H大腸がん）
- Cmab+Enco
- Cmab+Enco+Bini
- ENCO＋CET(q2w)
- ENCO＋BINI＋CET(q2w)
- CET(q2w)
- FOLFIRI+CET(q2w)
- IRI+CET(q2w)
- mFOLFOX6+CET(q2w)
- TRA＋PER
- sLV5FU2
- mFOLFOX6
- FOLFIRI
- SOX
- IRIS
- CAPIRI
- CAPIRI＋BEV
- mFOLFOXIRI
- S-1＋BEV
- mFOLFOX6+BEV
- FOLFIRI+BEV
- SOX＋BEV
- IRIS+BEV
- mFOLFOXIRI+BEV
- mFOLFOX6(周術期)
- CAPOX(周術期)